Capstone Therapeutics Corp. (CAPS)
USD 2.08
(-11.49%)
USD 2.08
(-11.49%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 20.27 Million USD | -29.55% |
| 2022 | 28.78 Million USD | 1.74% |
| 2021 | 28.29 Million USD | 35.96% |
| 2020 | 20.8 Million USD | 684.91% |
| 2019 | 2.65 Million USD | 187.84% |
| 2018 | 921 Thousand USD | -5.44% |
| 2017 | 974 Thousand USD | 286.51% |
| 2016 | 252 Thousand USD | 2391.12% |
| 2015 | -10.99 Thousand USD | 99.49% |
| 2014 | -2.16 Million USD | 65.42% |
| 2013 | -6.25 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 21.33 Million USD | -1.02% |
| 2024 Q1 | 21.55 Million USD | 6.31% |
| 2023 Q3 | 28.86 Million USD | -2.82% |
| 2023 FY | 20.27 Million USD | -29.55% |
| 2023 Q1 | 31.08 Million USD | 7.99% |
| 2023 Q2 | 29.7 Million USD | -4.43% |
| 2023 Q4 | 20.27 Million USD | -29.76% |
| 2022 Q4 | 28.78 Million USD | -8.21% |
| 2022 Q3 | 31.35 Million USD | 10.21% |
| 2022 FY | 28.78 Million USD | 1.74% |
| 2022 Q1 | 31.07 Million USD | 9.77% |
| 2022 Q2 | 28.45 Million USD | -8.45% |
| 2021 Q3 | 27.52 Million USD | -3.08% |
| 2021 Q4 | 28.31 Million USD | 2.86% |
| 2021 Q1 | 31.04 Million USD | 49.2% |
| 2021 FY | 28.29 Million USD | 35.96% |
| 2021 Q2 | 28.39 Million USD | -8.54% |
| 2020 Q4 | 20.8 Million USD | 59.9% |
| 2020 FY | 20.8 Million USD | 684.91% |
| 2020 Q3 | 13.01 Million USD | 0.0% |
| 2019 Q3 | 3.05 Million USD | 30.57% |
| 2019 Q4 | 3.05 Million USD | 0.0% |
| 2019 FY | 2.65 Million USD | 187.84% |
| 2019 Q1 | 1.49 Million USD | 31.57% |
| 2019 Q2 | 2.33 Million USD | 56.77% |
| 2018 FY | 921 Thousand USD | -5.44% |
| 2018 Q4 | 1.13 Million USD | 89.32% |
| 2018 Q3 | 599 Thousand USD | 835.94% |
| 2018 Q2 | 64 Thousand USD | -95.71% |
| 2018 Q1 | 1.49 Million USD | 53.08% |
| 2017 FY | 974 Thousand USD | 286.51% |
| 2017 Q1 | 514 Thousand USD | 70.2% |
| 2017 Q2 | 563 Thousand USD | 9.53% |
| 2017 Q3 | 441 Thousand USD | -21.67% |
| 2017 Q4 | 974 Thousand USD | 120.86% |
| 2016 FY | 252 Thousand USD | 2391.12% |
| 2016 Q4 | 302 Thousand USD | 337.8% |
| 2016 Q3 | -127 Thousand USD | -141.23% |
| 2016 Q2 | 308 Thousand USD | 9.22% |
| 2016 Q1 | 282 Thousand USD | 2663.87% |
| 2015 FY | -10.99 Thousand USD | 99.49% |
| 2015 Q4 | -10.99 Thousand USD | 98.27% |
| 2015 Q2 | -1.03 Million USD | 32.66% |
| 2015 Q1 | -1.54 Million USD | 28.84% |
| 2015 Q3 | -637 Thousand USD | 38.57% |
| 2014 Q3 | -3.02 Million USD | 10.25% |
| 2014 Q4 | -2.16 Million USD | 28.39% |
| 2014 FY | -2.16 Million USD | 65.42% |
| 2014 Q1 | -3.77 Million USD | 39.69% |
| 2014 Q2 | -3.36 Million USD | 10.78% |
| 2013 Q2 | -5.05 Million USD | 7.34% |
| 2013 FY | -6.25 Million USD | 0.0% |
| 2013 Q4 | -6.25 Million USD | -34.03% |
| 2013 Q3 | -4.66 Million USD | 7.54% |
| 2013 Q1 | -5.45 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 1547886.26% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -258.971% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 52.618% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 8222.747% |
| Rebus Holdings, Inc. | 305 Thousand USD | -6547.869% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 421.61% |
| Qrons Inc. | 351.42 Thousand USD | -5669.619% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -3157.901% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 53.318% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 99453.195% |
| Skye Bioscience, Inc. | -5.72 Million USD | 454.389% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | -28.63% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -392.372% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -4945.676% |
| SQZ Biotechnologies Company | -36.23 Million USD | 155.952% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -804.277% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -2086.832% |
| Mesoblast Limited | 55.85 Million USD | 63.701% |
| Marizyme, Inc. | 18.56 Million USD | -9.193% |
| Genus plc | 190.6 Million USD | 89.362% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -806.866% |
| Pharming Group N.V. | 109.8 Million USD | 81.534% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -2257.014% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -1570.335% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -2881.765% |
| ContraFect Corporation | -6.02 Million USD | 436.475% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -14959.53% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -1654.846% |
| IMV Inc. | 7.67 Million USD | -164.337% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -268.528% |
| MultiCell Technologies, Inc. | 90.04 USD | -22518780.498% |
| ONE Bio Corp. | 9.04 Million USD | -124.291% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 2862.481% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -56.62% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -1382.195% |
| Q BioMed Inc. | 4.06 Million USD | -399.408% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 33.639% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -1912.075% |
| Biomind Labs Inc. | 711.4 Thousand USD | -2750.147% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 66.511% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -914.108% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -58.325% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -5536.763% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -14403.162% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -101958.69% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -820.807% |
| GB Sciences, Inc. | 1.74 Million USD | -1060.408% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 11132.276% |
| HST Global, Inc. | 96.79 Thousand USD | -20847.796% |
| CSL Limited | 10.52 Billion USD | 99.807% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -9732.361% |
| Halberd Corporation | 144.72 Thousand USD | -13910.406% |
| Enzolytics Inc. | 981.65 Thousand USD | -1965.489% |
| Agentix Corp. | 37.63 Thousand USD | -53781.109% |
| Resverlogix Corp. | 6.45 Million USD | -214.308% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 3112.38% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.999% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 143.129% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -186.75% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -648.574% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 329.369% |
| AVAX Technologies, Inc. | -5.9 Million USD | 443.474% |
| Zenith Capital Corp. | 10.06 Thousand USD | -201370.588% |
| Genscript Biotech Corporation | -1.06 Billion USD | 101.91% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -10016.149% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -749.778% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -12225.162% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 110788.94% |
| Kadimastem Ltd | -253.1 Thousand USD | 8111.0% |
| Helix BioMedix, Inc. | -2.57 Million USD | 888.94% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | -353.398% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -9974.831% |
| LadRx Corporation | -2.03 Million USD | 1095.645% |
| Cell Source, Inc. | 9.23 Million USD | -119.628% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -3092.231% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -3092.231% |
| NovAccess Global Inc. | 2.17 Million USD | -830.747% |
| Affymax, Inc. | -5.59 Million USD | 462.265% |
| Itoco Inc. | 228.3 Thousand USD | -8781.102% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -14810.029% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -309.038% |
| Mobile Lads Corp. | 484.23 Thousand USD | -4087.249% |
| CytoDyn Inc. | 20.26 Million USD | -0.069% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 3133948.532% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 218866.252% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -163.12% |
| SYBLEU INC | 473.71 Thousand USD | -4180.22% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -354.923% |
| International Stem Cell Corporation | 2.59 Million USD | -682.857% |
| Bioxytran, Inc. | 1.89 Million USD | -967.768% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -32386.822% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -829.708% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -490.448% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -137.063% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -2524.361% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 1722.08% |
| Neutra Corp. | 52.18 Thousand USD | -38752.588% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 914.624% |
| PureTech Health plc | -167.19 Million USD | 112.127% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 8379.027% |
| IXICO plc | -4.44 Million USD | 556.195% |
| IntelGenx Technologies Corp. | 13.21 Million USD | -53.385% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 63.034% |
| CSL Limited | 10.52 Billion USD | 99.807% |
| Cellectis S.A. | -43.81 Million USD | 146.272% |